Systematic Analysis of the Glucose-PTS in Streptococcus sanguinis Highlighted its Importance in Central Metabolism and Bacterial Fitness

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Previous work reported that deletion of the Enzyme IIAB subunits (EIIAB Man , manL ) of the glucose phosphotransferase system (glucose-PTS, manLMNO) in Streptococcus sanguinis impacted carbon catabolite repression (CCR) and bacterial fitness. Here, a single nucleotide polymorphism in ManN, ManNA91E, produced the unusual phenotype of increased excretion of organic acids and H 2 O 2 , yet elevated PTS activities. To characterize the contributions of each component of the glucose-PTS to bacterial fitness, we performed genetic analyses by deleting from S. sanguinis SK36 the entire operon and each EII Man subunit individually; and genes encoding the catabolite control protein CcpA (Δ ccpA ) and the redox regulator Rex (Δ rex ) for comparison. Deletion of each subunit incurred a growth defect on glucose partly due to elevated excretion of H 2 O 2 ; when supplemented with catalase this defect was rescued, instead resulting in a significantly higher yield than the parent. All glucose-PTS deletion mutants presented an increased antagonism against the oral pathobiont Streptococcus mutans , a phenotype absent in Δ ccpA despite increased H 2 O 2 output. A shift in the pyruvate node towards mixed acid fermentation and increased arginine deiminase activity enhanced pH homeostasis in glucose-PTS mutants, but not Δ ccpA . Despite the purported ability of Rex to regulate central carbon metabolism, deletion of rex had no significant impact on most of the phenotypes discussed here. These findings place glucose-PTS in the pivotal position of controlling central carbon flux in streptococci, with critical outcomes impacting acidogenicity, aciduricity, pH homeostasis, and antagonism, highlighting its potential as a therapeutic target for treating diseases with a dysbiotic microbiome.

Article activity feed